An Overview of siRNA Delivery Strategies for Urological Cancers

被引:8
作者
Halib, Nadia [1 ]
Pavan, Nicola [2 ]
Trombetta, Carlo [2 ]
Dapas, Barbara [3 ]
Farra, Rossella [3 ]
Scaggiante, Bruna [3 ]
Grassi, Mario [4 ]
Grassi, Gabriele [3 ]
机构
[1] Univ Sains Islam Malaysia, Fac Dent, Dept Basic Sci & Oral Biol, Kuala Lumpur 55100, Malaysia
[2] Univ Trieste, Dept Med Surg & Hlth Sci, Urol Clin, I-34149 Trieste, Italy
[3] Trieste Univ, Cattinara Univ Hosp, Dept Life Sci, Str Fiume 447, I-34149 Trieste, Italy
[4] Trieste Univ, Dept Engn & Architecture, Via Valerio 6, I-34127 Trieste, Italy
关键词
bladder cancer; prostate cancer; renal cancer; siRNA; delivery; PROSTATE-CANCER; IN-VITRO; BLADDER-CANCER; DRUG-DELIVERY; SIOG GUIDELINES; ULTRASONIC DRUG; KINASE; NANOPARTICLES; EXPRESSION; CARCINOMA;
D O I
10.3390/pharmaceutics14040718
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) seems to be of great therapeutic interest. siRNAs are double-stranded RNA molecules which can specifically target virtually any mRNA of pathological genes. For this reason, siRNAs have a great therapeutic potential for human diseases including urological cancers. However, the fragile nature of siRNAs in the biological environment imposes the development of appropriate delivery systems to protect them. Thus, ensuring siRNA reaches its deep tissue target while maintaining structural and functional integrity represents one of the major challenges. To reach this goal, siRNA-based therapies require the development of fine, tailor-made delivery systems. Polymeric nanoparticles, lipid nanoparticles, nanobubbles and magnetic nanoparticles are among nano-delivery systems studied recently to meet this demand. In this review, after an introduction about the main features of urological tumors, we describe siRNA characteristics together with representative delivery systems developed for urology applications; the examples reported are subdivided on the basis of the different delivery materials and on the different urological cancers.
引用
收藏
页数:27
相关论文
共 50 条
[31]   Metabolic signature biomarkers for predicting the recurrence of urological cancers [J].
Amaro, Filipa ;
Carvalho, Marcia ;
Bastos, Maria de Lourdes ;
de Pinho, Paula Guedes ;
Pinto, Joana .
CLINICA CHIMICA ACTA, 2023, 549
[32]   The metabolic landscape of urological cancers: New therapeutic perspectives [J].
Miranda-Goncalves, Vera ;
Lameirinhas, Ana ;
Henrique, Rui ;
Baltazar, Fatima ;
Jeronimo, Carmen .
CANCER LETTERS, 2020, 477 :76-87
[33]   The role of lymphangiogenesis in lymphatic tumour spread of urological cancers [J].
Bolenz, Christian ;
Fernandez, Mario I. ;
Tilki, Derya ;
Herrmann, Edwin ;
Heinzelbecker, Julia ;
Erguen, Sueleyman ;
Stroebel, Philipp ;
Reich, Oliver ;
Michel, Maurice S. ;
Trojan, Lutz .
BJU INTERNATIONAL, 2009, 104 (05) :592-597
[34]   hTERT, hTR and TERT promoter mutations as markers for urological cancers detection: A systematic review [J].
Morozov, Andrey ;
Potoldykova, Natalya ;
Chinenov, Denis ;
Enikeev, Mikhail ;
Glukhov, Alexander ;
Shpikina, Anastasia ;
Goryacheva, Evgenia ;
Taratkin, Mark ;
Malavaud, Bernard ;
Enikeev, Dmitry .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (08) :498.e21-498.e33
[35]   Therapeutic Effects of Berberine against Urological Cancers: Biological Potentials Based on Cellular Mechanisms [J].
Savoji, Ali Bozorg ;
Kaheni, Yasamin ;
Rezaei, Pouria ;
Farkhondeh, Tahereh ;
Pourhanifeh, Mohammad Hossein ;
Samarghandian, Saeed .
CURRENT MOLECULAR MEDICINE, 2024, 24 (10) :1282-1290
[36]   DNA methylation-based biomarkers in urological cancers [J].
Xu, Rong ;
Lin, Shaokun ;
Xin, Jun ;
Guo, Youhong ;
Zhang, Wenzhou ;
Lin, Yangjun ;
Xu, Rui'an .
Information Technology Journal, 2013, 12 (17) :4289-4297
[37]   Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance [J].
Zhang, Zhibin ;
Gao, Zhixu ;
Fang, Huimin ;
Zhao, Yutang ;
Xing, Rong .
CANCER AND METASTASIS REVIEWS, 2024, 43 (03) :867-888
[38]   Gout patients have an increased risk of developing most cancers, especially urological cancers [J].
Chen, C-J ;
Yen, J-H ;
Chang, S-J .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 (05) :385-390
[39]   Vaginal siRNA delivery: overview on novel delivery approaches [J].
Krishna Baxi ;
Sujata Sawarkar ;
Munira Momin ;
Vainav Patel ;
Trinette Fernandes .
Drug Delivery and Translational Research, 2020, 10 :962-974
[40]   Engineering siRNA therapeutics: challenges and strategies [J].
Zaidi, Syed Saqib Ali ;
Fatima, Faria ;
Zaidi, Syed Aqib Ali ;
Zhou, Dezhong ;
Deng, Wuquan ;
Liu, Shuai .
JOURNAL OF NANOBIOTECHNOLOGY, 2023, 21 (01)